This question tests recognition and management of drug-induced hyperkalemia in a complex elderly patient. The key patient-specific factors are hyperkalemia (5.6 mEq/L), concurrent use of multiple potassium-increasing drugs (lisinopril, spironolactone), and NSAID use with reduced renal function. Discontinuing spironolactone is the best initial step because it directly increases potassium, and the combination with ACE inhibitor and NSAIDs creates dangerous synergy. Increasing spironolactone (A) would worsen hyperkalemia and risk cardiac arrhythmias. Adding potassium supplements (C) is contraindicated with existing hyperkalemia. Continuing current therapy (D) ignores a potentially life-threatening electrolyte abnormality requiring prompt intervention. The clinical pearl is that hyperkalemia risk increases exponentially when combining RAS inhibitors, potassium-sparing diuretics, and NSAIDs, especially in elderly patients with reduced renal function, requiring careful monitoring and often medication discontinuation to prevent cardiac complications.

This question tests the management of acute exacerbations in chronic obstructive pulmonary disease (COPD). The key patient-specific factor is the presence of increased sputum volume and purulence with low-grade fever, indicating a bacterial exacerbation in a GOLD group D patient. Starting prednisone 40 mg daily for 5 days and doxycycline 100 mg twice daily for 5 days is the best choice as systemic corticosteroids and antibiotics are recommended for moderate to severe COPD exacerbations with purulent sputum. Starting fluticasone nasal spray addresses allergies but not the exacerbation; propranolol may worsen bronchospasm; discontinuing tiotropium and scheduling albuterol ignores the need for steroids and antibiotics. GOLD guidelines emphasize short-course steroids and antibiotics for exacerbations with infection signs to reduce hospitalization risk. Patient-centered care includes smoking cessation counseling and monitoring for antibiotic side effects to improve long-term outcomes.

This question evaluates treatment selection for an acute COPD exacerbation with evidence of bacterial infection. The key patient-specific factors are purulent sputum, fever, and penicillin allergy requiring alternative antibiotic selection. The combination of prednisone and azithromycin is optimal because systemic corticosteroids reduce treatment failure and hospital admissions in COPD exacerbations, while azithromycin covers typical respiratory pathogens. Oseltamivir (B) treats influenza, not bacterial infections or COPD exacerbations. Starting fluticasone/salmeterol (C) during an acute exacerbation is inappropriate as maintenance therapy changes should occur when stable. Amoxicillin/clavulanate (D) is contraindicated due to penicillin allergy, and omitting corticosteroids reduces treatment effectiveness. The clinical framework emphasizes that moderate-to-severe COPD exacerbations require both systemic corticosteroids (typically 40 mg prednisone for 5 days) and antibiotics when bacterial infection is suspected, with antibiotic selection guided by local resistance patterns and patient allergies.

This question tests lipid management in patients with hypertension and CKD. The key patient-specific factor is LDL-C 190 mg/dL with CKD stage 2, warranting high-intensity statin for risk reduction. Starting atorvastatin 80 mg nightly is appropriate as high-intensity statins are recommended for high-risk patients per ACC/AHA guidelines. Ezetimibe monotherapy is insufficient; fenofibrate targets triglycerides; no therapy ignores risk. Guidelines emphasize statins in CKD for cardiovascular protection. Patient-centered care includes exercise promotion and liver monitoring for safety.

This question tests therapy modification in hypertension with diuretic side effects. The key patient-specific factor is elevated uric acid and low-normal potassium likely from hydrochlorothiazide, contributing to gout risk. Discontinuing hydrochlorothiazide and adding amlodipine 5 mg daily is necessary to avoid hyperuricemia while controlling blood pressure. Switching to chlorthalidone may worsen uric acid; adding indomethacin risks interactions; spironolactone needs monitoring. ACC/AHA guidelines suggest calcium channel blockers as alternatives. Patient-centered care includes diet counseling to manage gout and hypertension outcomes.

This question tests management of calcium channel blocker adverse effects. The key patient-specific factor is ankle edema post-amlodipine dose increase, with controlled blood pressure and occupational standing. Reducing amlodipine to 5 mg and considering losartan titration is best to alleviate edema while maintaining control. Adding furosemide is unnecessary; ibuprofen worsens edema; adding verapamil risks bradycardia. ACC/AHA guidelines support dose adjustment for tolerance. Patient-centered care addresses lifestyle factors like standing for edema prevention.

This question tests management of non-infectious COPD exacerbations. The key patient-specific factor is acute dyspnea post-viral infection without purulence, in a patient with osteoporosis. Starting prednisone 40 mg daily for 5 days is best as short-course systemic corticosteroids are recommended for acute exacerbations per GOLD guidelines. Amoxicillin is unnecessary without infection; fluticasone nasal is for rhinitis; theophylline is not first-line due to toxicity. Guidelines aim to reduce symptoms and relapse. Patient-centered care considers osteoporosis risk with steroids and promotes adherence for better control.

This question tests primary prevention statin therapy selection in a diabetic patient. The key patient-specific factor is diabetes mellitus in a patient aged 40-75 years, which automatically qualifies him for moderate-to-high intensity statin therapy regardless of calculated ASCVD risk. Atorvastatin 40 mg is the best choice as it provides high-intensity therapy appropriate for diabetic patients with additional risk factors (low HDL, elevated triglycerides). Fenofibrate monotherapy (B) primarily targets triglycerides but lacks the robust cardiovascular outcome data of statins. Ezetimibe monotherapy (C) is less effective than statins for primary prevention. Deferring therapy (D) is incorrect because diabetes alone warrants statin initiation in this age group. The clinical pearl is that all diabetic patients aged 40-75 should receive at least moderate-intensity statin therapy, with high-intensity statins preferred when additional ASCVD risk factors are present, following ACC/AHA cholesterol guidelines.

This question tests management of a significant drug interaction between warfarin and trimethoprim/sulfamethoxazole. The key patient-specific factor is the need for antibiotic therapy in a stable warfarin patient, where TMP/SMX inhibits warfarin metabolism and can dramatically increase INR. Arranging early INR monitoring with anticipated dose reduction is optimal because this interaction typically increases INR by 1.5-2 points within 3-5 days. Continuing unchanged (A) risks dangerous supratherapeutic INR and bleeding. Holding warfarin completely (B) may lead to subtherapeutic anticoagulation and stroke risk. Adding aspirin (D) increases bleeding risk without addressing the interaction. The clinical framework for managing warfarin interactions includes early monitoring, preemptive dose adjustments for known significant interactions, and close follow-up, with TMP/SMX being one of the highest-risk antibiotics requiring proactive management.

This question tests the management of statin-induced myopathy. The key patient-specific factor is elevated creatine kinase with muscle pain and grapefruit juice consumption, which increases simvastatin exposure. Stopping simvastatin and switching to pravastatin 40 mg nightly while avoiding grapefruit is best as pravastatin has lower interaction risk and equivalent efficacy. Continuing with coenzyme Q10 does not address the cause; increasing simvastatin worsens risk; adding gemfibrozil increases myopathy risk. ACC/AHA guidelines recommend switching statins for intolerance. Patient-centered care involves lifestyle adjustments and monitoring symptoms for safe lipid management.